Skip to main content
. Author manuscript; available in PMC: 2014 Mar 9.
Published in final edited form as: Cogn Behav Ther. 2013 Jan 15;42(1):64–76. doi: 10.1080/16506073.2012.751124

Table 5.

Psychiatric medications at admission and discharge, and change in psychiatric medications in 56 patients

Measure Number of subjects (%)
a. Psychiatric medications on admission a
None 6 (11%)
Antidepressants (TCAs, SSRIs, SNRIs, buproprion) 40 (71%)
Benzodiazepines 22 (39%)
Antipsychotics 23 (41%)
Mood stabilizers and anticonvulsants (e.g., lithium,
 valproic acid, gabapentin)
20 (36%)
Other (e.g., adderall, campral, methadone, trazodone) 17 (30%)
b. Psychiatric medications on discharge a
None 3 (5%)
Antidepressants 43 (77%)
Benzodiazepines 26 (46%)
Antipsychotics 35 (62%)
Mood stabilizers and anticonvulsants 23 (41%)
Other 26 (46%)
c. Change in psychiatric medications No changeb Added Removed
Antidepressants 51 (91%) 4 (7%) 1 (2%)
Benzodiazepines 42 (75%) 9 (16%) 5 (9%)
Antipsychotics 40 (71%) 14 (25%) 2 (4%)
Mood stabilizers and anticonvulsants 49 (88%) 5 (9%) 2 (4%)

Notes. SNRIs, serotonin and norepinephrine reuptake inhibitors (e.g., venlafaxine, duloxetine); SSRIs, selective serotonin reuptake inhibitors (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram); TCAs, tricyclic antidepressants (e.g., clomipramine).

a

The sum of the percentages exceeds 100% because polypharmacy was common.

b

The No Change category includes both those who were not taking the indicated class of medication at admission nor taking it at discharge, and those were were taking the indicated class medication at admission and continued to take it at discharge.